Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Oct 15, 2019

Keywords

ClinConnect Summary

This clinical trial is investigating whether adding radiation treatment after surgery can help patients with atypical meningioma, a type of brain tumor, live longer without their cancer coming back. Previous studies have shown mixed results, so researchers want to conduct a larger, well-structured study to get clearer answers on this important question. Participants will be individuals diagnosed with atypical meningioma who have had their entire tumor removed and meet specific criteria, such as being between the ages of 18 and 70 and not having had prior radiation therapy or other serious health issues.

If you or a loved one is eligible to participate, you can expect to be part of a multicenter study, meaning multiple hospitals will be involved. Participants will be randomly assigned to either receive radiation treatment after surgery or not, and doctors will closely monitor their health and cancer status over time. It's important to note that this trial is not yet recruiting, but it aims to provide valuable insights into the best care for patients after surgery for atypical meningioma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who underwent gross total resection at each center and were diagnosed as atypical meningioma (WHO class II) according to the WHO 2016 diagnostic criteria.
• • Gross total resection was defined as modified Simpson 1-3 and confirmed by postoperative magnetic resonance imaging.
• Exclusion Criteria:
• • age less than 18 years old or older than 70 years
• • meningioma recurrence
• • patients had previous radiotherapy
• • multiple meningioma
• • optic nerve sheath meningioma or other extracranial meningioma
• • tumor involving venous sinus
• • ECOG score ≥ 2 points
• • preoperative ASA grade ≥ 3
• • previous or current malignant tumors
• • pregnant or lactating women
• • Patients with Gd-DTPA allergies, spatial claustrophobia or pacemaker implantation that can not be conducted constract-enhanced head magnetic resonance examination
• • patients who were unable to obtain informed consent or refused to participate in the study.